Market Overview

UPDATE: Oppenheimer Upgraded Lannett Company and Set PT

Share:
Related LCI
Cramer Says Sell These 'Completely Untouchable' Stocks
Total System Services, Lannett And Fate Therapeutics Moving After-Hours
FDA clears Lannett's generic version of Merck's Temodar (Seeking Alpha)

Oppenheimer analyst Rohit Vanjani Upgraded Lannett (NYSE: LCI) from Perform to Outperform and set a $29 PT following Impax Labs price boost on generic digoxin.

Vanjani downgraded Lannett two days from Outperform to Perform and removed his $20 PT a mere two days ago. In Wednesday's note, the analyst cited the company's significant outperformance. Today's note focused on Oppenheimer's confidence that the LCI price boost won't be reverted as a competitor has followed suit. The $29 PT is $5 higher than Bloomberg's average PT data.

Lannet has quadrupled Year to Date versus the Russell 2000 Health Care (RGUSHS) which is up 42 percent.

Lannett closed at $21.50 on Thursday and is currently trading +11.3 percent.

Latest Ratings for LCI

DateFirmActionFromTo
Feb 2016Craig-HallumUpgradesBuy
Nov 2015Craig-HallumDowngradesBuyHold
Sep 2015Roth CapitalMaintainsBuy

View More Analyst Ratings for LCI
View the Latest Analyst Ratings

Posted-In: Oppenheimer Rohit VanjaniAnalyst Color Upgrades Price Target Analyst Ratings

 

Related Articles (LCI)

View Comments and Join the Discussion!

Get Benzinga's Newsletters